

# Contents

Contributors	xi
Preface	xv
Acknowledgments	xvii

## **Part I Introduction to Clinical Exercise Physiology 1**

### **Chapter 1 Introduction 3**

Jonathan K. Ehrman, PhD, Paul M. Gordon, PhD, MPH, Paul S. Visich, PhD, MPH,  
and Steven J. Keteyian, PhD

The Past, Present, and Future of Clinical Exercise Physiology . . . . .	3
Professional Organizations and Certifications Throughout the World . . . . .	10
Professionalization of Clinical Exercise Physiology . . . . .	13
Conclusion. . . . .	18

### **Chapter 2 Behavioral Approaches to Physical Activity Promotion 19**

Gregory W. Heath, DHSc, MPH

Benefits of Physical Activity. . . . .	19
Participation in Regular Physical Activity . . . . .	21
Conclusion. . . . .	30

### **Chapter 3 General Principles of Pharmacology 33**

Steven J. Keteyian, PhD

General Properties of Drugs . . . . .	33
Pharmacotherapy . . . . .	36
Conclusion. . . . .	42

### **Chapter 4 General Interview and Examination Skills 45**

Quinn R. Pack, MD

General Interview . . . . .	45
Physical Examination . . . . .	50
Conclusion. . . . .	58

### **Chapter 5 Graded Exercise Testing and Exercise Prescription 61**

Steven J. Keteyian, PhD

Exercise Testing . . . . .	61
Exercise Prescription . . . . .	76
Conclusion. . . . .	86

<b>Chapter 6</b>	<b>Diabetes</b>	<b>91</b>
Ann L. Albright, PhD		
	Definition . . . . .	91
	Scope . . . . .	91
	Pathophysiology . . . . .	92
	Clinical Considerations . . . . .	96
	Exercise Prescription . . . . .	101
	Exercise Training . . . . .	108
	Conclusion . . . . .	111
<b>Chapter 7</b>	<b>Obesity</b>	<b>113</b>
David C. Murdy, MD, and Jonathan K. Ehrman, PhD		
	Definition . . . . .	113
	Scope . . . . .	114
	Pathophysiology . . . . .	117
	Clinical Considerations . . . . .	120
	Exercise Prescription . . . . .	128
	Exercise Training . . . . .	132
	Conclusion . . . . .	133
<b>Chapter 8</b>	<b>Hypertension</b>	<b>137</b>
Aashish S. Contractor, MD, MEd, Terri L. Gordon, MPH, and Neil F. Gordon, MD, PhD, MPH		
	Definition . . . . .	137
	Scope . . . . .	138
	Pathophysiology . . . . .	139
	Clinical Considerations . . . . .	139
	Exercise Prescription . . . . .	145
	Exercise Training . . . . .	148
	Conclusion . . . . .	150
<b>Chapter 9</b>	<b>Hyperlipidemia and Dyslipidemia</b>	<b>155</b>
Peter W. Grandjean, PhD, Benjamin Gordon, MS, Paul G. Davis, PhD, and J. Larry Durstine, PhD		
	Definition . . . . .	155
	Scope . . . . .	158
	Pathophysiology . . . . .	160
	Clinical Considerations . . . . .	162
	Exercise Prescription . . . . .	168
	Exercise Training . . . . .	171
	Conclusion . . . . .	173
<b>Chapter 10</b>	<b>Metabolic Syndrome</b>	<b>177</b>
Mark D. Peterson, PhD, and Paul M. Gordon, PhD, MPH		
	Definition . . . . .	177
	Scope . . . . .	178
	Pathophysiology . . . . .	182
	Clinical Considerations . . . . .	185
	Exercise Prescription . . . . .	188
	Exercise Training . . . . .	192
	Conclusion . . . . .	194

**Chapter 11 End-Stage Renal Disease** 197

Samuel Headley, PhD, and Michael Germain, MD

Definition . . . . .	197
Scope . . . . .	197
Pathophysiology . . . . .	198
Clinical Considerations . . . . .	198
Exercise Prescription . . . . .	204
Exercise Training . . . . .	209
Conclusion. . . . .	210

**Part III Cardiovascular Diseases** 213

**Chapter 12 Acute Coronary Syndromes: Unstable Angina Pectoris and Acute Myocardial Infarction** 215

Ray W. Squires, PhD

Scope . . . . .	215
Pathophysiology . . . . .	215
Clinical Considerations . . . . .	220
Exercise Prescription . . . . .	229
Exercise Training for Overweight Coronary Patients . . . . .	232
Conclusion. . . . .	234

**Chapter 13 Revascularization of the Heart** 239

Mark A. Patterson, MEd

Definition . . . . .	239
Scope . . . . .	239
Pathophysiology . . . . .	240
Clinical Considerations . . . . .	241
Exercise Prescription and Training. . . . .	245
Conclusion. . . . .	254

**Chapter 14 Chronic Heart Failure** 259

Steven J. Keteyian, PhD

Definition . . . . .	259
Scope . . . . .	259
Pathophysiology . . . . .	259
Medical and Clinical Considerations . . . . .	261
Exercise Prescription . . . . .	268
Exercise Training . . . . .	273
Conclusion. . . . .	275

**Chapter 15 Peripheral Artery Disease** 277

Ryan J. Mays, PhD, Ivan P. Casserly, MB, BCh, and Judith G. Regensteiner, PhD

Definition . . . . .	277
Scope . . . . .	277
Pathophysiology . . . . .	278
Clinical Considerations . . . . .	278
Exercise Prescription . . . . .	289
Exercise Training . . . . .	291
Conclusion. . . . .	293

**Chapter 16 Cardiac Electrical Pathophysiology** **297**

Kerry J. Stewart, EdD, and David D. Spragg, MD

Definition . . . . .	297
Scope . . . . .	297
Pathophysiology . . . . .	298
Clinical Considerations . . . . .	300
Exercise Prescription and Training . . . . .	305
Conclusion. . . . .	312

**Part IV Diseases of the Respiratory System** **315**

**Chapter 17 Chronic Obstructive Pulmonary Disease** **317**

Ann M. Swank, PhD, and N. Brian Jones, PhD

Definition . . . . .	317
Scope . . . . .	318
Pathophysiology . . . . .	318
Clinical Considerations . . . . .	320
Exercise Prescription . . . . .	326
Exercise Training . . . . .	327
Conclusion. . . . .	333

**Chapter 18 Asthma** **337**

Brian W. Carlin, MD

Definition . . . . .	337
Scope . . . . .	337
Pathophysiology . . . . .	337
Clinical Considerations . . . . .	339
Exercise Prescription . . . . .	343
Exercise Training . . . . .	345
Conclusion. . . . .	347

**Chapter 19 Cystic Fibrosis** **351**

Michael J. Danduran, MS, and Julie Biller, MD

Definition . . . . .	351
Scope . . . . .	351
Pathophysiology . . . . .	351
Clinical Considerations . . . . .	353
Exercise Prescription . . . . .	362
Exercise Training . . . . .	369
Conclusion. . . . .	373

**Part V Oncology and the Immune System** **377**

**Chapter 20 Cancer** **379**

Dennis J. Kerrigan, PhD, John R. Schairer, DO, and Lee W. Jones, PhD

Definition . . . . .	379
Scope . . . . .	379
Pathophysiology . . . . .	380
Medical and Clinical Considerations . . . . .	385
Exercise Prescription . . . . .	388
Exercise Training . . . . .	392
Conclusion. . . . .	394

**Chapter 21 Human Immunodeficiency Virus** 397

Edward Archer, PhD, MS, Helmut Albrecht, MD, and Gregory A. Hand, PhD, MPH

Definition . . . . .	397
Scope . . . . .	398
Pathophysiology . . . . .	398
Clinical Considerations . . . . .	400
Exercise Prescription . . . . .	404
Exercise Training . . . . .	406
Conclusion. . . . .	413

**Part VI Disorders of the Bone and the Joints** 417

**Chapter 22 Arthritis** 419

Andrew B. Lemmey, PhD

Definition . . . . .	419
Scope . . . . .	419
Pathophysiology . . . . .	420
Clinical Considerations . . . . .	421
Exercise Prescription . . . . .	428
Exercise Training . . . . .	437
Conclusion. . . . .	443

**Chapter 23 Osteoporosis** 447

David L. Nichols, PhD, and Andjelka Pavlovic, MS

Definition . . . . .	447
Scope . . . . .	447
Pathophysiology . . . . .	448
Clinical Considerations . . . . .	448
Exercise Prescription . . . . .	452
Exercise Training . . . . .	456
Conclusion. . . . .	457

**Chapter 24 Nonspecific Low Back Pain** 461

Jan Perkins, PT, PhD, and J. Tim Zippel, PT, DSc

Definition . . . . .	461
Scope . . . . .	462
Pathophysiology . . . . .	462
Clinical Considerations . . . . .	463
Exercise Prescription and Training. . . . .	471
Conclusion. . . . .	482

**Part VII Selected Neuromuscular Disorders** 487

**Chapter 25 Spinal Cord Injury** 489

David R. Gater, Jr., MD, PhD, and Stephen F. Figoni, PhD

Definition . . . . .	489
Scope . . . . .	489
Pathophysiology . . . . .	490
Clinical Considerations . . . . .	494
Exercise Prescription and Training. . . . .	502
Exercise Training . . . . .	505
Conclusion. . . . .	509

## Chapter 26 Multiple Sclerosis 511

Linda H. Chung, PhD, and Jane Kent-Braun, PhD

Definition . . . . .	511
Scope . . . . .	511
Pathophysiology . . . . .	512
Clinical Considerations . . . . .	512
Exercise Prescription . . . . .	517
Exercise Training . . . . .	522
Conclusion . . . . .	524

## Chapter 27 Cerebral Palsy 529

Amy E. Rauworth, MS, and James H. Rimmer, PhD

Definition . . . . .	529
Scope . . . . .	530
Pathophysiology . . . . .	530
Clinical Considerations . . . . .	530
Exercise Prescription . . . . .	550
Exercise Training . . . . .	551
Conclusion . . . . .	556

## Chapter 28 Stroke 559

Christopher J. Womack, PhD

Definition . . . . .	559
Scope . . . . .	559
Pathophysiology . . . . .	561
Clinical Considerations . . . . .	561
Exercise Prescription . . . . .	564
Exercise Training . . . . .	566
Conclusion . . . . .	567

## Part VIII Special Populations 571

### Chapter 29 Children 573

Timothy J. Michael, PhD, and William A. Saltarelli, PhD

Definition . . . . .	573
Scope . . . . .	573
Clinical Considerations . . . . .	573
Exercise Prescription . . . . .	578
Exercise Training . . . . .	579
Conclusion . . . . .	582

### Chapter 30 Aging 589

Daniel E. Forman, MD, and Jerome L. Fleg, MD

Definition . . . . .	589
Scope . . . . .	589
Pathophysiology . . . . .	590
Clinical Considerations . . . . .	592
Exercise Prescription . . . . .	597
Exercise Training . . . . .	600
Conclusion . . . . .	602

**Chapter 31 Depression 605**

---

Krista A. Barbour, PhD, Benson M. Hoffman, PhD, and James A. Blumenthal, PhD

Definition . . . . . 605  
Scope . . . . . 605  
Pathophysiology . . . . . 606  
Clinical Considerations . . . . . 607  
Exercise Prescription and Training . . . . . 612  
Conclusion . . . . . 615

**Chapter 32 Intellectual Disability 617**

---

Bo Fernhall, PhD, and Tracy Baynard, PhD

Definition . . . . . 617  
Scope . . . . . 617  
Pathophysiology . . . . . 618  
Clinical Considerations . . . . . 620  
Exercise Prescription . . . . . 624  
Exercise Training . . . . . 626  
Conclusion . . . . . 629

Glossary 633  
References 655  
Index 741  
About the Editors 757